{"id":"shr-1316-chemotherapeutic","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"SHR-1316 is a microtubule-targeting chemotherapy that binds to tubulin and prevents microtubule assembly, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. This mechanism is typical of taxane or vinca alkaloid-class agents used across multiple solid tumor types.","oneSentence":"SHR-1316 is a chemotherapeutic agent that inhibits tubulin polymerization to disrupt microtubule dynamics and induce cancer cell death.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:29.616Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indications under phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT04316364","phase":"PHASE3","title":"A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-14","conditions":"Non-Small-Cell Lung Cancer","enrollment":537}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-1316、Chemotherapeutic","genericName":"SHR-1316、Chemotherapeutic","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-1316 is a chemotherapeutic agent that inhibits tubulin polymerization to disrupt microtubule dynamics and induce cancer cell death. Used for Solid tumors (specific indications under phase 3 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}